T Cell Responses to Dystrophin in a Natural History Study of Duchenne Muscular Dystrophy
Karen Anthony1,2,3, Pierpaolo Ala1,2, Francesco Catapano1,2, Jinhong Meng1,2, Joana
Domingos †1,2, Mark Perry1,2, Valeria Ricotti1,2, Kate Maresh1,2, Lauren C Phillips4,5, Laurent
Servais6, 7, 8, Andreea M Seferian9, Silvana De Lucia9, Imelda de Groot10, Yvonne D Krom11,
JGM Verschuuren11 Erik H Niks11, Volker Straub4, Michela Guglieri4, Thomas Voit,2, Jennifer
Morgan*1,2, Francesco Muntoni1,2.
1. The Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child
Health, London, UK.
2. National Institute for Health Research, Great Ormond Street Institute of Child Health
Biomedical Research Centre, University College London, London, UK
3. Centre for Physical Activity and Life Sciences, University of Northampton,
Northampton, UK.
4. John Walton Muscular Dystrophy Research Centre, Newcastle University and
Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
5. Department of Pharmacology, University of Oxford, Oxford, UK.
6. Institut de Myologie, Groupe hospitalier La Pitié Salpétrière, Paris, France.
7. MDUK Oxford Neuromuscular Center, University of Oxford, UK
8. Neuromuscular Center, Division of Paediatrics, University Hospital and University of
Liège, Belgium
9. I-Motion, Hopital Trousseau, Paris, France.
10. Radboud University Medical Centre, Nijmegen, Netherlands.
11. Leiden University Medical Centre, Leiden, Netherlands.
†
Deceased
*Corresponding author
Keywords
Duchenne muscular dystrophy, dystrophin, revertant fibres, immune response, ELISPOT
assay
Abstract
Duchenne muscular dystrophy (DMD) is caused by the lack of dystrophin, but many patients
have rare revertant fibres that express dystrophin. The skeletal muscle pathology of DMD
patients includes immune cell infiltration and inflammatory cascades. There are several
strategies to restore dystrophin in skeletal muscles of patients, including exon skipping and
gene therapy. There is some evidence that dystrophin restoration leads to a reduction in
immune cells, but dystrophin epitopes expressed in revertant fibres or following genome
editing, cell therapy or microdystrophin delivery after AAV gene therapy may elicit T cell
production in patients. This may affect the efficacy of the therapeutic intervention, and
potentially lead to serious adverse events.
To confirm and extend previous studies, we performed annual Enzyme- Linked Immunospot
interferon-gamma assays on peripheral blood mononuclear cells from 77 paediatric boys with
DMD recruited into a natural history study, 69 of whom (89.6%)
were treated with
corticosteroids. T cell responses to dystrophin were quantified using a total of 368 peptides
spanning the entire dystrophin protein, organized into nine peptide pools. Peptide mapping
pools were used to further localize the immune response in one positive patient.
Six (7.8%) patients had a T cell-mediated immune response to dystrophin at at least one
timepoint. All patients that had a positive result had been treated with corticosteroids, either
prednisolone or prednisone.
Our results show that ~8% of DMD individuals in our cohort have a pre-existing T cellmediated immune response to dystrophin despite steroid treatment. Although these
responses are relatively low-level, this information should be considered as a useful
immunological baseline before undertaking clinical trials and future DMD studies. We further
highlight the importance for a robust, reproducible standard operating procedure for collecting,
storing and shipping samples from multiple centres to minimise the number of inconclusive
data.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive, progressive neuromuscular
condition affecting 1:5000 male births (1). It is caused by mutations (mainly deletions) in the
DMD gene, that codes for the protein dystrophin (2). The lack of dystrophin in skeletal muscle
fibres causes them to degenerate; this is followed by cycles of regeneration/degeneration,
ultimately resulting in the progressive loss of skeletal muscle (reviewed (3)). Individuals with
DMD lose their ability to walk by their early teens, but corticosteroids can postpone the age at
which ambulation is lost by 3–4 years (4). Many approaches to restore dystrophin have been
tested pre-clinically and four antisense drugs (eteplirsen, golodirsen, viltolarsen and
casimersen) have been approved in the USA and a small molecule (ataluren) in Europe; these
drugs restore a small amount of functional dystrophin. In addition, adeno-associated viral
(AAV) gene therapy is a promising approach that is currently in clinical trials, e.g.
ClinicalTrials.gov Identifiers: NCT04240314 AAV9,
NCT02376816,
NCT00428935 and
NCT03368742 and EudraCT Number: 2020-002093-27.
There are several different dystrophin isoforms, but only the full-length dp427 is expressed in
skeletal muscle fibres (reviewed (1, 2)). Dystrophin is not always completely absent in skeletal
muscles of individuals with DMD: depending on the location of the mutation in the DMD gene,
shorter, partially functional or non-functional dystrophin protein may be produced (3). Many
patients and mouse models have a small percentage of “revertant” muscle fibres that express
truncated dystrophin protein (5)(reviewed (6)). These revertant fibres arise from aberrant,
stochastic splicing events that allow the production of small amounts of protein and the
resulting dystrophin epitopes expressed in them (7) might elicit T cell production. The latter
may accelerate an immune response to the restored dystrophin in treated patients (8) (9)
(reviewed (10)).
Alternatively, dystrophin expressed in revertant fibres may reduce the
immune response to myofibres expressing restored dystrophin (11).
But the timing of the
appearance of these revertant fibres is likely to be crucial. They are already present in
newborn mdx mouse muscles (7) and in DMD fetal muscle (4) and their prenatal onset is likely
to induce tolerance to the expressed epitopes.
It has been shown that increasing age correlates with an increased risk for a T cell-mediated
immune response to dystrophin and in a previous cross-sectional study on 70 individuals with
DMD, approximately 50% of the steroid naïve and 20% of the steroid treated population were
reported to have circulating dystrophin primed T cells (9). To confirm and extend these
observations, we performed a multicentre, longitudinal natural history study, to determine
whether patients with DMD had a pre-existing T cell-mediated immune response to dystrophin,
and whether this changed over time. We performed Enzyme- Linked Immunospot (ELISPOT)
IFN-gamma assays on individuals recruited into this four-year DMD natural history study that
recruited 50 ambulant and 27 non-ambulant boys with DMD from four clinical centres.
ELISPOT assays on all patients were performed with a full-length dystrophin peptide set; we
also studied one individual who had an exon-skippable deletion with peptides corresponding
to unique epitopes generated by the potential exon skipping event. We correlated our data to
factors such as age, ambulation status, steroid regime and DMD deletion.
Methods
Subjects
Blood samples from DMD subjects belonging to a cohort of boys enrolled in the Association
Francaise contre les Myopathies (AFM)-funded iMDEX multicentre natural history study were
used for our experiments. Specimens from subjects recruited in London (Centre 1), Newcastle
(Centre 2), Paris (Centre 3), and Leiden (Centre 4) were analyzed. All the samples used for
this project are listed in Table 1.
This study was approved in the UK by the Bromley Research Ethics committee (REC
12/LO/0442), and the ethical committee of all the other institutions. All subjects and their legal
representatives provided written informed consent for the study. This study is registered with
the Clinical Trial Gov website with the number NCT02780492.
Boys with DMD were assessed annually over up to four years with an ELISPOT IFN-γ assay
performed with a full-length dystrophin peptide set as previously described (8, 9). A patient
with an exon skippable deletion was additionally assessed with peptides corresponding to
unique epitopes that would have been generated in the case of a single exon skipping
intervention to restore the reading frame. We also assessed four healthy adult controls as
well as six neuromuscular disease controls from female children with non-dystrophinopathies.
These consisted of one individual with muscle-eye-brain disease (6 years of age), four with
limb girdle muscular dystrophy (9-16 years of age) and one with Ullrich congenital muscular
dystrophy (14 years of age).
Sample collection and preparation
5-20 ml (ideally, at least 10 ml) of blood was collected from individuals into either heparin
tubes, or Vacutainer® CPT™ Cell Preparation Tubes with sodium citrate. All samples were
stored at room temperature for a maximum of 24 hours before processing. Samples from the
two UK sites were delivered to UCL as blood within 24 hours and processed. Samples from
France and the Netherlands were processed locally, and frozen peripheral blood mononuclear
cells (PBMCs) shipped on dry ice to minimise loss of cell viability during shipment. A
standardised procedure was used by all blood processing sites. Briefly, an equal volume of
phosphate buffered saline (PBS) was added and a maximum of 20ml of diluted blood was
carefully layered on top of 15 ml Ficoll. The tubes were centrifuged at 400g for 30 minutes at
room temperature with slow acceleration and no brake. Plasma was removed, aliquoted and
stored at -80°C; some of these samples were used for miRNA assays (12). The peripheral
blood mononuclear cell (PBMC) layer was extracted and washed three times with 30ml PBS
and centrifugation at 100g for 10 minutes at room temperature, with the brake on and high
acceleration. The cell pellet was resuspended in chilled freezing medium (10% DMSO, 90%
FCS) in 1ml aliquots (~10-20 million PBMCs/ml) and frozen in a Mr Frosty at -80°C overnight.
When required, cells were thawed rapidly at 37°C, resuspended in 5 ml warmed AIM-V
medium (AIM-V: Invitrogen, 12055-091) containing 2% human serum (Human AB serum,
Gemini Bio Products 100-512, heat inactivated for 30 minutes at 56°C) and a count of viable
cells was performed.
Peptides
20mer peptides overlapping by 10 amino acids that span the entire dystrophin protein were
used (Proimmune Ltd, Oxford, UK). There was a total of 368 peptides, organized into 9
peptide pools (8) (Figure 1). Stock vials of individual peptides at 5mg/ml were made up in
10% DMSO, 90% sterile water and stored at -80°C. Peptide pools were made up at 40 µg/ml
(of each peptide), diluted in sterile water and kept at -80°C in small aliquots. Peptide mapping
pools were used to further localize the immune response in a subset of positive individuals. In
the mapping pools, each peptide is present in two sub-pools.
ELISPOT assay
Peripheral blood T cell responses to dystrophin were quantified using the ELISPOT assay (8).
This was performed using the Human IFN-gamma Elispot kit (U-CyTech, CT230-PB5) and
Millipore IP filter plates (Millipore, S2EM004M99) according to the manufacturers’ instructions.
3x105 cells were plated/well when screening for dystrophin responses and 75,000 cells/well
were plated for the positive control or polyclonal stimulation. Concanavalin A (Sigma C0412)
at final concentration of 2.5 µg/ml in PBS was used as a stimulus positive control. For peptide
stimulations, the peptide pools were used at 1-2 µg/ml final concentration for each peptide.
Cells were plated in duplicate wells, with a total volume of 200 µl (100 µl cells, 95 µl medium,
5 µl antigen). The ELISPOT plate was covered with a lid and incubated at 37C, 5-7% CO2
and 100% humidity for 24-36 hours.
Spots were imaged and counted using an automated AID reader. The same camera and
count settings was used for all samples. Each well was manually assessed to remove any
debris mistaken as spots. Over 50% saturation was considered too numerous to count. The
intensity was set to a minimum of 20 brightness units and the spot size set as 40-500 pixels
with a minimum gradient of 5 degrees. In line with Flanigan et al, a result was considered
positive only when both duplicates were > 15 SFC/106 PBMCs (8). We used this low
threshold after discussion with Dr Mendell’s group, whose reported responses to dystrophin
are typically very low level (8). For further confidence, in order to record a positive result, the
positive control (patient’s PBMCs reaction to Concanavalin A) must also be > 15 SFC/106
PBMCs and the negative control (patient’s PBMCs without stimulation) must be < 5 SFC/106
PBMCs.
Results
Boys with DMD were assessed annually (or semi-annually for patient 1.1) over three (and in
one case four) years with an ELISPOT IFN-γ assay performed with a full-length dystrophin
peptide set (9). The results are summarised in Figure 1 and Table 1 (full data in
(Supplementary Table S1). Twenty three patients from Centre 1, twenty patients from Centre
2, twenty three patients from Centre 3 and eleven patients from Centre 3 were included,
ranging from 5-18 years of age. Details of the different steroid regimes are summarised in
Supplementary Table S2. Thirty six were on prednisolone, sixteen were on deflazacort, fifteen
were on prednisone, two were on prednisone followed by deflazacort. Of the participants that
remained on the same treatment throughout, thirty nine were on a daily regime (fourteen
prednisolone, fourteen deflazacort and eleven prednisone) and twenty seven were on an
intermittent regime (twenty two prednisolone, two deflazacort and three prednisone).
A total of six (8%) individuals were positive at the first baseline visit (Figure 2). The positive
epitopes are located before, and/or after the patient’s deletion with no apparent associations
(Supplementary Table 3). All individuals that had a positive result had been treated with
corticosteroids (five with prednisolone and one with prednisone); two were ambulant and four
were non-ambulant and ranged from 6-16 years of age (Supplementary Table 1). None of the
sixteen deflazacort-treated patients had a positive result. We compared the rates of positive
results between individuals that had been treated with prednisone, prednisolone, deflazacort,
prednisone followed by deflazacort, compared to those on no/discontinued treatment and
between individuals that had been treated with prednisolone compared to deflazacort, using
a Fishers Exact Test. We found no significant differences between the any of the groups
(deflazacort vs no/discontinued treatment - p=1; prednisone vs no/discontinued treatment p=1; prednisolone vs no/discontinued treatment - p=0.5661; prednisone followed by
deflazacort vs no/discontinued treatment - p=0.2; prednisolone vs deflazacort P = 0.3077).
The positive individuals had deletions in exons 45 (2 patients), 42-43, 48-50, 52 and 45-52
(Supplementary Tables 1 and 3 ). These mutations are expected to lead to the lack of fulllength dystrophin (Dp427), but all should have been able to produce the shorter dystrophin
proteins Dp116, Dp71 and Dp40, and one patient would be expected to produce Dp140
(Supplementary Table 3). None of these shorter dystrophin proteins, with the exception of
Dp71 (13), are expressed in skeletal muscle (14).
Due to the frequent occurrence of inconclusive results (defined below) at subsequent
timepoints, we were unable to capture full longitudinal data on all individuals. Longitudinal data
for two participants is presented in Figure 3. Patient 1.1 (patient 1 from Centre 1), carrying an
exon 45 deletion, had an extremely strong response to peptide pool 7 (peptides encoded by
exons 50-59) at baseline, which remained the strongest response among all pools at all
subsequent visits (Figure 3). In contrast, patient 1.18, also deleted for exon 45, was only
weakly positive for peptide pool 7 at baseline and 1-year follow-up but then showed a strong
response to several peptide pools (including pool 7) at the 3-year visit (Figure 3).
Since patient 1.1 had a consistently strong response to peptide pool 7 at all timepoints, we
performed additional ELISPOT assays using the mapping pool for peptide pool 7 at the zero
and six-months timepoints (Figure 4). At the zero-year timepoint, this patient was positive for
pools 7C, 7L, 7M and 7N, which together map to peptides encoded for by exon 54. The patient
was also positive for pools 7A, 7L, 7M and 7N which maps to peptides encoded for by exon
51.
In summary, 4% of ambulant and 14.8% of non-ambulant patients had a T cell response to
dystrophin. The mean ages of ambulant and non-ambulant patients at the start of the study
were 8 and 14 years respectively. All the positive patients were taking prednisolone (five
patients) or prednisone (one patient). Of the patients in our study taking prednisolone, 13.9%
returned a positive ELISPOT result. Only eight patients had not been treated with
corticosteroids and these either had a negative, or an inconclusive, result.
One patient (1.14, Supplementary table 1) with an exon 48-50 deletion, theoretically skippable
for exon 51, was additionally assessed with peptides corresponding to unique junctional
epitopes that would be generated by exon skipping. In this patient, the unique junctional
epitope did not have a positive response, despite being positive to the full-length dystrophin
peptide set (Figure 5). We also analysed four healthy adult controls and six disease controls
which all returned a negative result (data not shown).
On the occasions when either the positive control was not positive, the negative control was
positive and/or there were not enough viable cells to perform the assay samples were scored
as inconclusive (Supplementary table 1, marked with *). Sampling issues contributing to
insufficient viable cells included the patient not attending the clinic, the appointment being
cancelled, failure to take a blood sample, insufficient blood taken (a relatively high volume of
blood (at least 10 ml) is required), or poor cell count and/or viability. There were (with rare
exceptions) not enough cells remaining to perform repeat assays in cases where the original
results were inconclusive. The assay was repeated on patient 3.1 at the first timepoint: the
repeated assay was also inconclusive, as the negative control (patient’s PBMCs without
stimulation) was greater than 5 SFC/106 PBMCs on both occasions.
Conclusions/Discussion
When designing clinical trials to restore dystrophin, it is important to identify patients that have
a pre-existing T cell mediated immune response to dystrophin. It is also important to establish
a natural history baseline and to try to understand factors that might affect this immune
response and how it might be attenuated so that it does not interfere with treatment. This is
especially important when considering AAV-mediated gene therapy approaches, which in preclinical work elicit significant dystrophin restoration (reviewed (15-17)), although similar
considerations apply to any experimental therapy employed to restore dystrophin, from
genome editing to cell therapy. The fact that none of the neuromuscular disease controls had
a T cell response to dystrophin suggests that a pathological muscle environment, including
inflammation (reviewed (18)), does not on its own play an obvious role in the process; . The
muscle fibres of patients with other types of neuromuscular disease contain dystrophin, so
they would have been tolerised to the protein. Our findings indicate that this tolerance was not
broken by the immune cells, which would include T cells, that are present within pathological
muscle. howeverHowever, our small control group size is a limitation and a larger set of
disease control individuals should be studied to conclusively address this question.
The ELISPOT assay is a highly sensitive and widely used immunoassay that measures the
frequency of cytokine-secreting cells at the single-cell level (reviewed (19)). It is in theory
easy to perform and provides both qualitative and quantitative information. Pre-existing
cellular immune responses to dystrophin have already been reported and quantified using the
ELISPOT assay (8, 9). The assay has also been used to examine T lymphocyte responses to
dystrophin in a clinical trial of AAV-minidystrophin, showing that some patients had an immune
response either before the start of treatment (2/6 patients), or after treatment (4/6 patients)(9).
These patients were given prednisolone 4 hours before treatment. In contrast, none of the 6
dogs included in a preclinical study of AAV-microdystrophin (that were transiently
immunosuppressed with cyclosporine and mycophenolate mofetil had a post-treatment T cell
response to dystrophin, but pre-treatment response was not quantified. (20).
T cell-mediated immune responses to dystrophin in patients enrolled in our study were
relatively rare and occurred at a fairly low level. Approximately 9% (6/69) of steroid treated
DMD individuals had a pre-existing T cell-mediated immune response to dystrophin. A lower
percentage of patients in our cohort had a response to dystrophin than in a previous study (8),
which reported that 20/70 (29%) of patients had T cell immunity against dystrophin. In this
study, ninety-one subjects were enrolled, including 70 patients with DMD and 21 age-matched
normal control subjects. Among the patients with DMD, 29 were treated with deflazacort, 24
were treated with prednisone and 17 were untreated. This may be due to the fact that the
majority of our patients (69/77) were on corticosteroids, which would reduce the inflammatory
response that occurs as part of the pathological process in dystrophin-deficient skeletal
muscle (reviewed (21, 22)) and which may exacerbate any T cell response. In addition, the
ages of the patients in the two studies were slightly different – from 4-18 years of age at the
start of our study, and from 3-25 years of age in the Flanigan et al. study (8). As older subjects
were shown to have an increased probability of having an immune response to dystrophin (8),
it is possible that the different ages of the subjects in the two studies may have contributed to
the different findings. But we cannot determine whether, as previously suggested (8), a
smaller percentage of patients that had been steroid treated compared to non-treated have
an immune response to dystrophin, as we had so few patients (5/77) that were steroid-naïve
(and none of these had a T cell response). The fact that all our positive patients were on
prednisolone or prednisone is in accordance with Flanigan et al., who found a lower incidence
of T cell response in patients treated with deflazacort than prednisolone (8). But But we only
had sixteen deflazacort-treated patients in our study, which is too few to draw any firm
conclusions. we found no significant differences in the percentage of individuals that had a T
cell response between those treated with either deflazacort or prednisolone. However, we
only had sixteen deflazacort-treated patients in our study, which is too low to draw any firm
conclusions.
Interestingly, the shorter dystrophin protein products not affected by the genomic deletions,
which are therefore expected to be produced by the patients studied (Supplementary Table
2) did not appear to give any protection by tolerising against epitopes that they share with fulllength dystrophin (Dp427).
Revertant fibres, that are present in approximately 50% of
individuals with DMD, might either tolerise the individuals, or induce an immune response to
dystrophin. The fact that the number of revertant fibres does not change much with time (5)
and our findings that individuals often have a T cell response to dystrophin at one timepoint
but not at others, argues against the idea that dystrophin in revertant fibres is eliciting the
response.
Pre-existing immunity may be more of an issue in patients treated by gene therapy, which
induces considerably higher levels of dystrophin production than exon skipping. In support of
this, out of the 12 patients that had AON (Eteplirsen)-mediated restored dystrophin, there was
no T cell response to dystrophin after 6 months of treatment (8). Nevertheless, it is still
important to identify, and if possible control, any immune response to dystrophin in patients
both before they embark on any treatment intended to restore dystrophin and at timepoints
after the onset of treatment.
Unfortunately, we encountered some issues that gave rise to inconclusive results in a high
percentage of our assays (Supplementary Table 1). These included high background levels
in negative controls that may be due to difficulties in processing blood within 24 hours.
Twenty-three patients had an inconclusive result at their first timepoint. If these patients are
removed from the analyses, then 11% of all patients had a positive result at at least one
timepoint. Of all 185 assays performed, 74 (40%) had an inconclusive result. Eleven patients
had either an inconclusive result, or sample problems at every timepoint. These problems
may well have skewed our findings. To overcome such problems, we suggest that centre(s)
collecting blood samples also isolate and freeze the PBMCs and send these, rather than the
entire blood sample, to the laboratory doing the analysis. Obtaining a sufficient volume of
blood (at least 10ml to achieve enough duplicate wells of 3x105 PBMCs/well) to isolate PBMCs
can be challenging especially for younger DMD patients and those with neurobehavioural
difficulties.
Despite the missing data indicated above, our longitudinal study clearly identified the T -cell mediated immune response to dystrophin in two DMD patients who were simply followed using
standards of care. We complement and extend previous studies and show for the first time
that having another type of muscular dystrophy, in which dystrophin is present, does not
appear to in itself to elicit an immune response to dystrophin. In line with the fact that an
individual’s immunological memory response can vary over time, we show that an individual’s
overall natural immune response to dystrophin, and response frequency can vary, as two
patients that were positive at early timepoints were negative at the year 3 timepoint. Earlier
work has suggested that the likelihood of an immune response to dystrophin increases with
age (5). In our cohort, four out of the six patients who has a positive response were above the
mean age (9 years) at the start of the study.
Overall, it is likely that the responses we observed are a result of low avidity T cells that haven’t
quite escaped tolerance mechanisms. We cannot rule out cross-reactive responses from
peptides that might be present in other proteins; it is also important to consider that each
patient, even if they have the same deletion, will likely have different HLA types which might
govern different responses. Our findings highlight the need for a robust, reproducible standard
operating procedure for collecting, storing and shipping samples and for performing for assay,
so that different intra and inter-laboratory operators achieve comparable results. Such a
protocol could be used to routinely monitor patients’ T cell response to dystrophin, especially
in gene therapy clinical trials for DMD.
Further investigations of the T cell response might include use of the FluoroSpot assay, which
utilizes fluorochrome-conjugated detection antibodies thereby allowing the simultaneous
detection of several individual cytokines and subsequent analysis of T cell sub-populations
(23, 24). It would also be of interest to determine whether there is an anti-dystrophin humoral
response in ELISPOT positive patients.
In conclusion, our results show that pre-existing T cell responses to dystrophin are uncommon
(8%), inconsistent and low-level. Whilst this does provide some confidence for dystrophin
restorative treatments, the fact that some patients are responsive warrants that baseline T cell
response should be considered before interpreting any data from dystrophin restoration.
Figure legends
Figure 1.
The location of the nine dystrophin peptide pools are illustrated in relation to the structural
features of the dystrophin protein. An example of ELISPOT wells from one patient (Centre 1,
patient 14; (Supplementary Table 1 ) at the 0-year timepoint is provided.
The table
summarises the results of the six positive patients at the 0-year timepoint showing which
peptide pools returned a positive result.
Figure 2.
Graphs plotting the average (±SEM) IFN-γ SFCs/106 PBMCs values across each peptide pool
for: A) a representative example of a negative sample (patient 1.11 at the 0-year timepoint);
B) positive patient 1.1; C) positive patient 1.7; D) positive patient 1.14; E) positive patient 1.18;
F) positive patient 2.15 and G) positive patient 3.3. The dotted line represents the positive
cut-off value of 15 SFCs/106 PBMCs; note both duplicates must be >15 to be considered
positive. Where a bar reaches 200 SFCs/106 PBMCs, the spots were too numerous to count.
Figure 3.
ELISPOT results for patients 1.1 (A) and 1.18 (B) over time. The graphs plot the average
(±SEM) IFN-γ SFCs/106 PBMCs values across each peptide pool. The dotted line represents
the positive cut-off value of 15 SFCs/106 PBMCs; note both duplicates must be >15 to be
considered positive.
Where a bar reaches 200 SFCs/106 PBMCs, the spots were too
numerous to count.
Figure 4.
Results from mapping pool 7 at zero (A) and 6-months (B) timepoints (patient 1.1). The graphs
plot the IFN-γ SFCs/106 PBMCs values across each mapping pool. The dotted line represents
the positive cut-off value of 15 SFCs/106 PBMCs; note both duplicates must be >15 to be
considered positive.
Figure 5.
Graph plotting the average (±SEM) IFN-γ SFCs/106 PBMCs values for a peptide pool
corresponding to the unique epitopes that would be generated by exon 51 skipping for patient
1.14 (48-50 deletion). A peptide pool for the unskipped scenario was also tested. The dotted
line represents the positive cut-off value of 15 SFCs/106 PBMCs; note both duplicates must
be >15 to be considered positive.
Acknowledgements
We acknowledge Dr Katie Campbell, Prof. Kevin Flanigan, Prof. Christopher Walker and Prof.
Jerry Mendell for sharing their ELISPOT expertise. We would like to thank Dr Valentina
Sardone for her help in preparing cells and Dr Petra Disterer for her assistance. We thank
Georgia Stimpson for statistical advice. The support of the MRC Centre for Neuromuscular
Diseases Biobank is gratefully acknowledged. JEM was supported by Great Ormond Street
Hospital Children’s Charity. This research was supported by the NIHR Great Ormond Street
Hospital Biomedical Research Centre. The views expressed are those of the author(s) and
not necessarily those of the NHS, the NIHR or the Department of Health.
References
1.
Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al.
Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol.
2012;71(3):304-13.
2.
Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The TREATNMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy
mutations. Hum Mutat. 2015;36(4):395-402.
3.
Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular
dystrophy. Nat Rev Dis Primers. 2021;7(1):13.
4.
Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, et al. The NorthStar
Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of
clinical trials. J Neurol Neurosurg Psychiatry. 2016;87(2):149-55.
5.
Arechavala-Gomeza V, Kinali M, Feng L, Guglieri M, Edge G, Main M, et al. Revertant
fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials.
Neuromuscul Disord. 2010;20(5):295-301.
6.
Lu QL. Revertant Phenomenon in DMD and LGMD2I and Its Therapeutic Implications:
A Review of Study Under Mentorship of Terrence Partridge. J Neuromuscul Dis.
2021;8(s2):S359-S67.
7.
Lu QL, Morris GE, Wilton SD, Ly T, Artem'yeva OV, Strong P, et al. Massive idiosyncratic
exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces
functional revertant fibers by clonal expansion. J Cell Biol. 2000;148(5):985-96.
8.
Flanigan KM, Campbell K, Viollet L, Wang W, Gomez AM, Walker CM, et al. Antidystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid
treatment effect. Hum Gene Ther. 2013;24(9):797-806.
9.
Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin
immunity in Duchenne's muscular dystrophy. N Engl J Med. 2010;363(15):1429-37.
10.
Moore MJ, Flotte TR. Autoimmunity in a genetic disease-a cautionary tale. N Engl J
Med. 2010;363(15):1473-5.
11.
Ferrer A, Wells KE, Wells DJ. Immune responses to dystropin: implications for gene
therapy of Duchenne muscular dystrophy. Gene Ther. 2000;7(17):1439-46.
12.
Catapano F, Scaglioni D, Maresh K, Ala P, Domingos J, Selby V, et al. Novel freecirculating and extracellular vesicle-derived miRNAs dysregulated in Duchenne muscular
dystrophy. Epigenomics. 2020;12(21):1899-915.
13.
Kawaguchi T, Niba ETE, Rani AQM, Onishi Y, Koizumi M, Awano H, et al. Detection of
Dystrophin Dp71 in Human Skeletal Muscle Using an Automated Capillary Western Assay
System. Int J Mol Sci. 2018;19(6).
14.
Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins,
multiple phenotypes. Lancet Neurol. 2003;2(12):731-40.
15.
Duan D. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular
Dystrophy Patients. Hum Gene Ther. 2018;29(7):733-6.
16.
Crudele JM, Chamberlain JS. AAV-based gene therapies for the muscular dystrophies.
Hum Mol Genet. 2019;28(R1):R102-R7.
17.
Asher DR, Thapa K, Dharia SD, Khan N, Potter RA, Rodino-Klapac LR, et al. Clinical
development on the frontier: gene therapy for duchenne muscular dystrophy. Expert Opin
Biol Ther. 2020;20(3):263-74.
18.
Tidball JG, Welc SS, Wehling-Henricks M. Immunobiology of Inherited Muscular
Dystrophies. Compr Physiol. 2018;8(4):1313-56.
19.
Yang F, Patton K, Kasprzyk T, Long B, Gupta S, Zoog SJ, et al. Validation of an IFNgamma ELISpot assay to measure cellular immune responses against viral antigens in nonhuman primates. Gene Ther. 2021.
20.
Shin JH, Pan X, Hakim CH, Yang HT, Yue Y, Zhang K, et al. Microdystrophin ameliorates
muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther.
2013;21(4):750-7.
21.
Quattrocelli M, Zelikovich AS, Salamone IM, Fischer JA, McNally EM. Mechanisms and
Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy. J Neuromuscul Dis.
2021;8(1):39-52.
22.
Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, Fischer D, et al. Standard of
care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can
we do better? Orphanet J Rare Dis. 2021;16(1):117.
23.
Janetzki S. Immune monitoring technology primer: the enzyme-linked immunospot
(Elispot) and Fluorospot assay. J Immunother Cancer. 2015;3:30.
24.
Korber N, Behrends U, Hapfelmeier A, Protzer U, Bauer T. Validation of an
IFNgamma/IL2 FluoroSpot assay for clinical trial monitoring. J Transl Med. 2016;14(1):175.
Table 1. Summary of elispot results
Cohort
Control (healthy)
Control (disease)
DMD total
DMD ambulant
DMD non-ambulant
DMD no/discontinued
steroids
DMD deflazacort
DMD prednisone
DMD prednisolone
DMD prednisone
followed by
deflazacort
Total
5
6
77
50
27
8
No. positive
0
0
6
2
4
0
% positive
0
0
7.8
4
14.8
0
16
15
36
2
0
0
0
13.9
50
5
1
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5